Abstract 2766
Background
Chemotherapy-induced peripheral neuropathy (CIPN) is an important factor that renders the continuation of chemotherapy difficult. Prevention and treatment of CIPN are indispensable in improving patients’ quality of life and promoting the continuation of chemotherapy that may improve survival. Numbness and pain are currently evaluated using subjective methods such as the visual analogue scale (VAS). However, the assessment of pain can vary greatly depending on the mood and physical state of the patient at the time of assessment. In this stage, objective evaluation methods have not been used for evaluations of CIPN in clinical trials because they have not been established as quantified evaluation methods for CIPN yet. A method to quantify CIPN objectively and easily is necessary. The PainVision PS-2100 (PV) is an analytical instrument that was designed to quantitatively and objectively assess sense perception and nociception in patients. The advantage of PV is that it can evaluate pain in a relatively short time, as well as assess pain without causing further pain to patients.
Methods
We examined a total of 73 CIPN patients with metastatic CRC received chemotherapy between April 2014 and December 2015 by using VAS, the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (NTX), the Disk-Criminator™ test, the monofilament test and PV. And then, we evaluated the correlation between subjective and objective evaluation methods or correlation between PV and other objective evaluation methods for CIPN.
Results
The average VAS (hand), VAS (foot) and PV scores of CIPN were 18.4 (range: 0–100), 23.8 (range: 0–100) and 24.7 (range: 0–496), respectively. A strong positive correlation was found between VAS (hand) and VAS (foot) scores (r = 0.798). The VAS (hand), VAS (foot), NTX 2, NTX 4 and NTX 8 significantly correlated with PV. PV showed no correlation with a Disk-Criminator™ or the monofilament test used as an objective evaluation.
Conclusions
This is the 1st report regarding the correlation between PV and other objective evaluation methods in CIPN patients. The evaluation of CIPN is complicated because numerous factors are involved. And further research and effort are needed to improve objective evaluation of CIPN by PV.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3909 - Spectrum of pathogenic germline mutations in Chinese lung cancer patients through next-generation sequencing
Presenter: Ying Huang
Session: Poster Display session 1
Resources:
Abstract
3061 - Poor prognostic impact of NTRK2 gene variation in Esophageal Squamous Cell Carcinoma
Presenter: Ye Chen
Session: Poster Display session 1
Resources:
Abstract
4735 - Mutation profile of Tibetan lung cancer revealed by Whole Exome Sequencing
Presenter: Xin Wang
Session: Poster Display session 1
Resources:
Abstract
5236 - Synergistic activity between niraparib and chemotherapy in colorectal cancer: molecular determinants from a preclinical model
Presenter: Pietro Paolo Vitiello
Session: Poster Display session 1
Resources:
Abstract
4051 - cRGDfK (cRGD) conjugated Pyropheophor¬bide-a (Pyro), a new tumor photodynamic agent, is highly accumulated and specific in tumor cell killing
Presenter: Fengwei Wang
Session: Poster Display session 1
Resources:
Abstract
859 - The expression of MMR, CD133 and the presence of p53 wt predict the response to Cabazitaxel in malignant neural tumors cell lines.
Presenter: Kevin Doello
Session: Poster Display session 1
Resources:
Abstract
2497 - IKS01, a next generation antibody drug conjugate (ADC) designed to be efficacious in tumors with low and moderate levels of folate receptor expression
Presenter: Jenny Thirlway
Session: Poster Display session 1
Resources:
Abstract
1636 - Novel Non-Camptothecin Compounds with Antiproliferative Activities against Breast Cancer Cells
Presenter: Wen-shan Li
Session: Poster Display session 1
Resources:
Abstract
3443 - Sensitization of estrogen receptor-positive breast cancer cells to tamoxifen by novel epi-oligomycin A
Presenter: Margarita Yastrebova
Session: Poster Display session 1
Resources:
Abstract
840 - Autophagy inhibition enhances leflunomide-induced cytotoxicity in human bladder cancer cells
Presenter: Li Cheng
Session: Poster Display session 1
Resources:
Abstract